Original French opinion adopted by the Transparency Committee.

The legally binding text is the original French opinion version.

SUMMARY

eplontersen

WAINZUA 45 mg

solution for injection in pre-filled pen

Inclusion on list

Adopted by the Transparency Committee on 2 September 2025

Summary of opinion

Favourable opinion for reimbursement in the “treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy”.

Transparency Committee’s conclusions

Clinical Benefit

- Hereditary transthyretin-mediated amyloidosis with stage 1 or 2 polyneuropathy is a rare, serious, incapacitating disease with a significant impact on quality of life and a fatal outcome.
- This is a preventive medicinal product.
- The efficacy/adverse effects ratio is modest, given the limitations of the study, reducing the scope of the efficacy results observed with eplontersen, and the absence of any available comparison versus a clinically relevant comparator.
- There are therapeutic alternatives; however, treatment with WAINZUA (eplontersen) cannot be ranked compared to its clinically relevant comparators and should not be favoured over the available alternatives.

→ Public health benefit

Considering:

- the seriousness of the disease and its prevalence,
- the identified medical need for effective, well-tolerated therapeutic alternatives, promoting compliance,
- the partial response to the identified need, due to:
- the lack of evidence of an additional impact on morbidity and mortality compared to the available alternatives, in the absence of any comparative data supplied versus a clinically relevant comparator,

- the lack of any expected impact on the organisation of care in the absence of any data supplied,

WAINZUA (eplontersen) is unlikely to have an additional impact on public health.

Considering all of these elements, the Committee deems that the clinical benefit of WAINZUA 45 mg (eplontersen) solution for injection in pre-filled pen is moderate in the MA indication.

The Committee issues a favourable opinion for inclusion of WAINZUA (eplontersen) in both the list of covered drugs for outpatients and the list of covered drugs for inpatients approved for use in the indication and at the MA dosages.

➔ **Recommended reimbursement rate for inclusion in the list of covered drugs for outpatients: 30%**

Clinical Added Value

Considering:

- evidence of the superiority of eplontersen versus placebo in NEURO-TTRansform, a randomised, open-label phase 3 trial, for the change in serum TTR concentration and the change in mNIS+7 score,
- evidence of an improvement in quality of life, assessed by the Norfolk QOL-DN, quality of life score, as a co-primary endpoint in the NEURO-TTRansform study,
- the design of the study and its methodological limitations, i.e. an indirect comparison of the eplontersen group with an external historic placebo group from the Neuro-TTR study, which was the pivotal study for inotersen [TEGSEDI], which reduces the scope of the efficacy results observed,
- the absence of any available comparison versus a clinically relevant comparator, despite the fact that a direct comparison versus ONPATTRO (patisiran), TEGSEDI (inotersen) or VYNDAQEL (tafamidis) or a methodologically robust indirect study versus AMVUTTRA (vutrisiran) could have been feasible,
- the limited duration of the study, of 18 months, which is insufficient to guarantee maintenance of efficacy in this chronic disease.
- the safety profile of eplontersen that seems to be favourable, with follow-up limited to 18 months,

the Committee deems that WAINZUA 45 mg (eplontersen) solution for injection in pre-filled pen provides no clinical added value (CAV V) in the current care pathway, which includes the relevant comparators.